Home › Funds › Prosight Management, LP › CRNX

Prosight Management, LP position in CRNX

CRINETICS PHARMACEUTICALS IN

Prosight Management, LP reported holding 374,666 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$14.0M, representing 2.42% of its reported portfolio and ranking #15 among its reported holdings. Prosight Management, LP has disclosed CRNX holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)374.67K sh
Reported value held$14.02M
Portfolio Weight2.42%
First reportedQ2 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Prosight Management, LP's CRNX position evolved

Prosight Management, LP first disclosed a stake in CRNX in Q2 2025 at 298,123 shares (US$8.6M). The position peaked in Q2 2026 at 374,666 shares, worth US$14.0M. Across 5 filings, Prosight Management, LP increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 374,666 shares valued at US$14.0M — an increase of 24,666 shares quarter over quarter.. Notable position changes include a 33% increase in Q1 2026.

Quarter by quarter

QuarterSharesValueChange
Q2 2025 298.12K $8.57M New
Q3 2025 328.68K $13.69M Add
Q4 2025 262.90K $12.24M Reduce
Q1 2026 350.00K $12.71M Add
Q2 2026 374.67K $14.02M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRNX and 13F data

CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 38 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRNX

All CRNX fund holders →

FAQ

How long has Prosight Management, LP held CRNX?

Prosight Management, LP has disclosed CRNX holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is Prosight Management, LP's current position in CRNX?

As of Q2 2026, Prosight Management, LP holds 374.67K shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $14.02M, representing 2.42% of its reported portfolio and ranking #15.

Has Prosight Management, LP been buying or selling CRNX?

In the latest 13F filing (Q2 2026), Prosight Management, LP increased its position in CRNX. The position peaked in Q2 2026 at 374.67K shares.

Which other funds hold CRNX?

Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.